Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kinder Morgan Inc (KMI) vs BIO-TECHNE Corp (TECH) Price & Performance

Kinder Morgan IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Kinder Morgan Inc vs BIO-TECHNE Corp — how do they compare? Kinder Morgan Inc trades at $32.51 (market cap $72.48B), while BIO-TECHNE Corp trades at $71.52 (market cap $11.16B). The key difference: Kinder Morgan Inc is far larger — about 6.5× BIO-TECHNE Corp's market cap, and Kinder Morgan Inc pays the higher dividend (3.61%). Which is the better fit depends on your goals.

KMITECH
Market Cap
$72.48B$11.16B
Sector
EnergyHealth
52-Week High
$34.31$72.12
52-Week Low
$25.84$43.31
Enterprise Value
$104.36B$11.24B
Dividend Yield
3.61%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kinder Morgan Inc

Kinder Morgan (KMI) trades at $32.71, up 1.27% with neutral technical signals. The company shows strong fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margin improving to 18.04%. Recent Q1 2026 earnings beat expectations with $0.48 EPS versus $0.40 expected. KMI maintains a $10.1B project backlog focused on natural gas infrastructure, supporting future growth. Analyst sentiment is mixed with 47% buy ratings but technical indicators show neutral momentum near key support at $32.

KMI presents a balanced opportunity with stable cash flows from fee-based contracts and dividend yield near 4%. Upside potential exists from LNG export growth and power demand, though valuation appears fair at P/E of 21.7. Key risks include commodity price exposure and high debt levels at $29.7B long-term. The stock offers income stability but limited near-term catalysts given neutral technical positioning.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.

The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.

Returns comparison

Trailing returns across standard periods

About Kinder Morgan Inc

Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.

Read more on KMI

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH